Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection - PubMed (original) (raw)
Comparative Study
doi: 10.1371/journal.pmed.0040192.
Roger H Brookes, Annette Fox, Dolly Jackson-Sillah, David J Jeffries, Moses D Lugos, Simon A Donkor, Ifedayo M Adetifa, Bouke C de Jong, Alex M Aiken, Richard A Adegbola, Keith P McAdam
Affiliations
- PMID: 17564487
- PMCID: PMC1891317
- DOI: 10.1371/journal.pmed.0040192
Comparative Study
Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection
Philip C Hill et al. PLoS Med. 2007 Jun.
Abstract
Background: Very little longitudinal information is available regarding the performance of T cell-based tests for Mycobacterium tuberculosis infection. To address this deficiency, we conducted a longitudinal assessment of the enzyme-linked immunosorbent spot test (ELISPOT) test in comparison to the standard tuberculin skin test (TST).
Methods and findings: In tuberculosis (TB) contacts we repeated ELISPOT tests 3 mo (n = 341) and 18 mo (n = 210) after recruitment and TSTs at 18 mo (n = 130). We evaluated factors for association with conversion and reversion and investigated suspected cases of TB. Of 207 ELISPOT-negative contacts, 51 (24.6%) had 3-mo ELISPOT conversion, which was associated with a positive recruitment TST (odds ratio [OR] 2.2, 95% confidence interval [CI] 1.0-5.0, p = 0.048) and negatively associated with bacillus Calmette-Guérin (BCG) vaccination (OR 0.5, 95% CI 0.2-1.0, p = 0.06). Of 134 contacts, 54 (40.2%) underwent 3-mo ELISPOT reversion, which was less likely in those with a positive recruitment TST (OR 0.3, 95% CI 0.1-0.8, p = 0.014). Between 3 and 18 mo, 35/132 (26.5%) contacts underwent ELISPOT conversion and 28/78 (35.9%) underwent ELISPOT reversion. Of the 210 contacts with complete results, 73 (34.8%) were ELISPOT negative at all three time points; 36 (17.1%) were positive at all three time points. Between recruitment and 18 mo, 20 (27%) contacts had ELISPOT conversion; 37 (50%) had TST conversion, which was associated with a positive recruitment ELISPOT (OR 7.2, 95% CI 1.4-37.1, p = 0.019); 18 (32.7%) underwent ELISPOT reversion; and five (8.9%) underwent TST reversion. Results in 13 contacts diagnosed as having TB were mixed, but suggested higher TST sensitivity.
Conclusions: Both ELISPOT conversion and reversion occur after M. tuberculosis exposure. Rapid ELISPOT reversion may reflect M. tuberculosis clearance or transition into dormancy and may contribute to the relatively low reported ELISPOT conversion rate. Therefore, a negative ELISPOT test for M. tuberculosis infection should be interpreted with caution.
Conflict of interest statement
Competing Interests: RHB has a patent relating to ex vivo ELISPOT licensed through Oxford University.
Figures
Comment in
- Serial testing for tuberculosis: can we make sense of T cell assay conversions and reversions?
Pai M, O'Brien R. Pai M, et al. PLoS Med. 2007 Jun;4(6):e208. doi: 10.1371/journal.pmed.0040208. PLoS Med. 2007. PMID: 17564491 Free PMC article.
Similar articles
- Comparison of two interferon gamma release assays in the diagnosis of Mycobacterium tuberculosis infection and disease in The Gambia.
Adetifa IM, Lugos MD, Hammond A, Jeffries D, Donkor S, Adegbola RA, Hill PC. Adetifa IM, et al. BMC Infect Dis. 2007 Oct 25;7:122. doi: 10.1186/1471-2334-7-122. BMC Infect Dis. 2007. PMID: 17961228 Free PMC article. - Using ELISPOT to expose false positive skin test conversion in tuberculosis contacts.
Hill PC, Jeffries DJ, Brookes RH, Fox A, Jackson-Sillah D, Lugos MD, Donkor SA, de Jong BC, Corrah T, Adegbola RA, McAdam KP. Hill PC, et al. PLoS One. 2007 Jan 31;2(1):e183. doi: 10.1371/journal.pone.0000183. PLoS One. 2007. PMID: 17264885 Free PMC article. - Interferon-gamma release assays for diagnosing mycobacterium tuberculosis infection in renal dialysis patients.
Winthrop KL, Nyendak M, Calvet H, Oh P, Lo M, Swarbrick G, Johnson C, Lewinsohn DA, Lewinsohn DM, Mazurek GH. Winthrop KL, et al. Clin J Am Soc Nephrol. 2008 Sep;3(5):1357-63. doi: 10.2215/CJN.01010208. Epub 2008 Jun 11. Clin J Am Soc Nephrol. 2008. PMID: 18550653 Free PMC article. - Interferon gamma release assays: principles and practice.
Lalvani A, Pareek M. Lalvani A, et al. Enferm Infecc Microbiol Clin. 2010 Apr;28(4):245-52. doi: 10.1016/j.eimc.2009.05.012. Epub 2009 Sep 24. Enferm Infecc Microbiol Clin. 2010. PMID: 19783328 Review. - Can ELISpot replace the tuberculin skin test for latent tuberculosis?
Greveson K. Greveson K. Br J Nurs. 2009 Nov 12-25;18(20):1248-54. doi: 10.12968/bjon.2009.18.20.45120. Br J Nurs. 2009. PMID: 20081663 Review.
Cited by
- Association between Gc genotype and susceptibility to TB is dependent on vitamin D status.
Martineau AR, Leandro AC, Anderson ST, Newton SM, Wilkinson KA, Nicol MP, Pienaar SM, Skolimowska KH, Rocha MA, Rolla VC, Levin M, Davidson RN, Bremner SA, Griffiths CJ, Eley BS, Bonecini-Almeida MG, Wilkinson RJ. Martineau AR, et al. Eur Respir J. 2010 May;35(5):1106-12. doi: 10.1183/09031936.00087009. Epub 2009 Sep 24. Eur Respir J. 2010. PMID: 19797128 Free PMC article. - Short-term reproducibility of a commercial interferon gamma release assay.
Detjen AK, Loebenberg L, Grewal HM, Stanley K, Gutschmidt A, Kruger C, Du Plessis N, Kidd M, Beyers N, Walzl G, Hesseling AC. Detjen AK, et al. Clin Vaccine Immunol. 2009 Aug;16(8):1170-5. doi: 10.1128/CVI.00168-09. Epub 2009 Jun 17. Clin Vaccine Immunol. 2009. PMID: 19535542 Free PMC article. - TB Summit 2014: prevention, diagnosis, and treatment of tuberculosis-a meeting report of a Euroscicon conference.
Maitra A, Bhakta S. Maitra A, et al. Virulence. 2014 Jul 1;5(5):638-44. doi: 10.4161/viru.29803. Epub 2014 Jul 8. Virulence. 2014. PMID: 25003368 Free PMC article. - Targeting Unconventional Host Components for Vaccination-Induced Protection Against TB.
Nemes E, Khader SA, Swanson RV, Hanekom WA. Nemes E, et al. Front Immunol. 2020 Jul 24;11:1452. doi: 10.3389/fimmu.2020.01452. eCollection 2020. Front Immunol. 2020. PMID: 32793199 Free PMC article. Review. - Comparison of two interferon gamma release assays in the diagnosis of Mycobacterium tuberculosis infection and disease in The Gambia.
Adetifa IM, Lugos MD, Hammond A, Jeffries D, Donkor S, Adegbola RA, Hill PC. Adetifa IM, et al. BMC Infect Dis. 2007 Oct 25;7:122. doi: 10.1186/1471-2334-7-122. BMC Infect Dis. 2007. PMID: 17961228 Free PMC article.
References
- Ewer K, Deeks J, Alvarez L, Bryant G, Waller S, et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet. 2003;361:1168–1173. - PubMed
- Hill PC, Brookes RH, Fox A, Fielding K, Jeffries DJ, et al. Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia. Clin Infect Dis. 2004;38:966973. - PubMed
- Ferrara G, Losi M, D'Amico R, Roversi P, Piro R, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: A prospective study. Lancet. 2006;367:1328–1334. - PubMed
- Ewer K, Millington KA, Deeks JJ, Alvarez L, Bryant G, et al. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis . Am J Respir Crit Care Med. 2006;174:831–839. - PubMed
- Wilkinson KA, Kon OM, Newton SM, Meintjes G, Davidson RN, et al. Effect of treatment of latent tuberculosis infection on the T cell response to Mycobacterium tuberculosis antigens. J Infect Dis. 2006;193:354–359. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical